Cardiovascular complications are observed in up to one-third of patients with systemic sclerosis (SSc). Early identification and management of SSc-associated primary cardiac disease is often challenging, given the complex disease pathophysiology, significant variability in clinical presentation, and scarce disease-modifying therapeutics. Here, we review the molecular mechanisms involved in SSc-associated cardiac disease pathogenesis, novel diagnostic tools and emerging therapies.
NurmohamedMTHeslingaMKitasGD.Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol2015; 11: 693–704.
3.
TyndallAJBannertBVonkM, et alCauses and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis2010; 69(10): 1809–1815.
4.
SchiopuEAuKMMcMahonMA, et alPrevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford)2014; 53(4): 704–713.
5.
FanYBenderSShiW, et alIncidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. J Manag Care Spec Pharm2020; 26(12): 1539–1547.
6.
SteenVDMedsgerTA.Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis2007; 66(7): 940–944.
7.
ButtSAJeppesenJLTorp-PedersenC, et alCardiovascular manifestations of systemic sclerosis: a Danish Nationwide Cohort Study. J Am Heart Assoc2019; 8: e013405.
8.
HinzeAMPerinJWoodsA, et alDiastolic dysfunction in systemic sclerosis: risk factors and impact on mortality. Arthritis Rheumatol2022; 74(5): 849–859.
9.
JamesSLAbateDAbateKH, et alGlobal, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2018; 392: 1789–1858.
10.
JonesXMFoxRMotawakelJ, et alReversal of right ventricular pressure loading improves function independent of fibrosis. J Physiol2023; 601: 397–399.
11.
RossLPriorDProudmanS, et alDefining primary systemic sclerosis heart involvement: a scoping literature review. Semin Arthritis Rheum2019; 48(5): 874–887.
12.
LamCSPSolomonSD. Classification of heart failure according to ejection fraction. J Am Coll Cardiol2021; 77: 3217–3225.
13.
AhlersMJLoweryBDFarber-EgerE, et alHeart failure risk associated with rheumatoid arthritis–related chronic inflammation. J Am Heart Assoc2020; 9: e014661.
14.
DhakalBPKimCHAl-KindiSG, et alHeart failure in systemic lupus erythematosus. Trends Cardiovasc Med2018; 28: 187–197.
15.
BairkdarMDongZAndellP, et alArrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study. RMD Open2024; 10: e004532.
16.
FairleyJLRossLQuinlivanA, et alSudden cardiac death, arrhythmias and abnormal electrocardiography in systemic sclerosis: a systematic review and meta-analysis. Semin Arthritis Rheum2023; 62: 152229.
17.
PatelHAggarwalNTRaoA, et alMicrovascular disease and small-vessel disease: the nexus of multiple diseases of women. J Womens Health (Larchmt)2020; 29(6): 770–779.
18.
MasiSRizzoniDTaddeiS, et alAssessment and pathophysiology of microvascular disease: recent progress and clinical implications. Eur Heart J2021; 42: 2590–2604.
19.
GdowskiMAMurthyVLDoeringM, et alAssociation of isolated coronary microvascular dysfunction with mortality and major adverse cardiac events: a systematic review and meta-analysis of aggregate data. J Am Heart Assoc2020; 9: e014954.
20.
GaleaNRosatoEGiganteA, et alEarly myocardial damage and microvascular dysfunction in asymptomatic patients with systemic sclerosis: a cardiovascular magnetic resonance study with cold pressor test. PLoS ONE2020; 15(12): e0244282.
21.
MannDL.The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res2011; 108: 1133–1145.
22.
SuurmondJDiamondB.Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest2015; 125(6): 2194–2202.
23.
HillMBPhippsJLCartwrightRJ, et alAntibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol2003; 106: 491–497.
24.
Cabral-MarquesORiemekastenG.Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun Rev2016; 15: 690–694.
25.
AbrahamDDistlerO.How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther2007; 9(suppl. 2): S2.
26.
DowsonCSimpsonNDuffyL, et alInnate Immunity in Systemic Sclerosis. Curr Rheumatol Rep2017; 19: 2.
27.
Al-DhaherFFPopeJEOuimetJM.Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum2010; 39(4): 269–277.
28.
PanopoulosSBourniaVKKonstantonisG, et alPredictors of morbidity and mortality in early systemic sclerosis: long-term follow-up data from a single-centre inception cohort. Autoimmun Rev2018; 17(8): 816–820.
29.
DeBergeMShahSJWilsbacherL, et alMacrophages in heart failure with reduced versus preserved ejection fraction. Trends Mol Med2019; 25(4): 328–340.
30.
Ortega-FerreiraCSoretPRobinG, et alAntibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis. Nat Commun2023; 14: 5291.
31.
SuthaharNMeijersWCSilljéHHW, et alGalectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics2018; 8(3): 593–609.
32.
SansonettiMWaleczekFJGJungM, et alResident cardiac macrophages: crucial modulators of cardiac (patho)physiology. Basic Res Cardiol2020; 115: 77.
33.
LavineKJEpelmanSUchidaK, et alDistinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc Natl Acad Sci USA2014; 111: 16029–16034.
34.
JonesXMRogersRTsiK.Macrophages contribute to cardiac fibrosis and diastolic dysfunction in systemic sclerosis. JACC Basic Transl Sci2024; 9(12): 1432–1434.
35.
CampitielloRSoldanoSGotelliE, et alThe intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: a systematic review. Autoimmun Rev2024; 23(10): 103637.
36.
LavineKJPintoAREpelmanS, et alThe macrophage in cardiac homeostasis and disease. J Am Coll Cardiol2018; 72: 2213–2230.
37.
Moreno-MoralABagnatiMKoturanS, et alChanges in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk. Ann Rheum Dis2018; 77(4): 596–601.
38.
MosserDMEdwardsJP.Exploring the full spectrum of macrophage activation. Nat Rev Immunol2008; 8(12): 958–969.
39.
TrombettaACSoldanoSContiniP, et alA circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res2018; 19: 186.
40.
ChristmannRBSampaio-BarrosPStifanoG, et alAssociation of interferon- and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis. Arthritis Rheumatol2014; 66(3): 714–725.
41.
Higashi-KuwataNJinninMMakinoT, et alCharacterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther2010; 12(4): R128.
42.
MathaiSKGulatiMPengX, et alCirculating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest2010; 90(6): 812–823.
43.
Al-AdwiYWestraJvan GoorH, et alMacrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology2023; 62: 535–545.
44.
AllanoreYWungPSoubraneC, et alA randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis2020; 79(12): 1600–1607.
45.
SoldanoSTrombettaACContiniP, et alIncrease in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis2018; 77(12): 1842–1845.
46.
WeberBNPaikJJAghayevA, et alNovel imaging approaches to cardiac manifestations of systemic inflammatory diseases. J Am Coll Cardiol2023; 82: 2128–2151.
47.
HumbertMKovacsGHoeperMM, et al2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J2023; 61: 2200879.
48.
MercurioVHinzeAMHummersLK, et alEssential hypertension worsens left ventricular contractility in systemic sclerosis. J Rheumatol2021; 48(8): 1299–1306.
49.
CiurzyńskiMBieniasPIrzykK, et alHeart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci2014; 3: 445–454.
50.
TennøeAHMurbræchKAndreassenJC, et alLeft ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. J Am Coll Cardiol2018; 72: 1804–1813.
51.
MoonJCMessroghliDRKellmanP, et alMyocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson2013; 15: 92.
52.
NtusiNAPiechnikSKFrancisJM, et alSubclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis—a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson2014; 16: 21.
53.
KnightDSKariaNColeAR, et alDistinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging2023; 24: 463–471.
54.
MarwickTHNeubauerSPetersenSE.Use of cardiac magnetic resonance and echocardiography in population-based studies: why, where, and when?Circ Cardiovasc Imaging2013; 6(4): 590–596.
55.
LengaYKohAPereraAS, et alOsteopontin expression is required for myofibroblast differentiation. Circ Res2008; 102: 319–327.
56.
AzabNARadyHMMarzoukSA.Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol2012; 31(9): 1359–1364.
57.
ParkJ-SOhYParkYJ, et alTargeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nat Commun2019; 10: 1128.
58.
VasanRS.Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation2006; 113: 2335–2362.
59.
PaikJJChoiDYMukherjeeM, et alTroponin elevation independently associates with mortality in systemic sclerosis. Clin Exp Rheumatol2022; 40(10): 1933–1940.
60.
WelshPPreissDHaywardC, et alCardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes. Circulation2019; 139: 2754–2764.
61.
BissellL-AAndersonMBurgessM, et alConsensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology2017; 56: 912–921.
62.
CaforioALPAdlerYAgostiniC, et alDiagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J2017; 38: 2649–2662.
63.
NinagawaKKatoMTsunetaS, et alBeneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study. Rheumatology2023; 62: 2550–2555.
64.
De SantisMTonuttiAMottaF, et alAdd-on rituximab for primary heart involvement associated with systemic sclerosis: a step forward in the tailored treatment of myocarditis?Eur J Heart Fail. Epub ahead of print 24 September 2024. DOI: 10.1002/ejhf.3467.
65.
KhannaDLinCJFFurstDE, et alTocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med2020; 8(10): 963–974.
66.
LeeZCNovianiMYapJ, et alTocilizumab for systemic sclerosis with cardiac involvement: a case report. Clin Exp Rheumatol2022; 40(10): 2006–2007.
67.
KhanKXuSNihtyanovaS, et alClinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis2012; 71(7): 1235–1242.
68.
LevyPDLaribiSMebazaaA.Vasodilators in acute heart failure: review of the latest studies. Curr Emerg Hosp Med Rep2014; 2(2): 126–132.
69.
TaiCGanTZouL, et alEffect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord2017; 17: 257.
70.
ValentiniGHuscherDRiccardiA, et alVasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis2019; 78(11): 1576–1582.
71.
DumitruRBBissellLAErhayiemB, et alSubclinical systemic sclerosis primary heart involvement by cardiovascular magnetic resonance shows no significant interval change. ACR Open Rheumatol2023; 5(2): 71–80.
72.
VolkmannERVargaJBlazarBR, et alChallenges and solutions for cellular therapy development in autoimmune diseases. Lancet Rheumatol2024; 6(11): e740–e743.
SullivanKMGoldmuntzEAKeyes-ElsteinL, et alMyeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med2018; 378: 35–47.
75.
Van LaarJMFargeDSontJK, et alAutologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA2014; 311: 2490.
76.
EbataSYoshizakiAObaK, et alSafety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol2021; 3(7): e489–e497.
77.
HoriiMFushidaNIkedaT, et alCytokine-producing B-cell balance associates with skin fibrosis in patients with systemic sclerosis. J Dermatol2022; 49(10):1012–1019.
78.
MatsushitaTKobayashiTMizumakiK, et alBAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv2018; 4(7): eaas9944.
79.
KalekarLACohenJNPrevelN, et alRegulatory T-cells in skin are uniquely poised to suppress profibrotic immune responses. Sci Immunol2019; 4: eaaw2910.
80.
PehlivanKCDuncanBBLeeDW.CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep2018; 13(5): 396–406.
81.
RosenbaumL.Tragedy, perseverance, and chance—the story of CAR-T therapy. N Engl J Med2017; 377: 1313–1315.
82.
BergmannCMüllerFDistlerJHW, et alTreatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis2023; 82(8): 1117–1120.
83.
MüllerFTaubmannJBucciL, et alCD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N Engl J Med2024; 390: 687–700.
84.
RurikJGTombáczIYadegariA, et alCAR T cells produced in vivo to treat cardiac injury. Science2022; 375: 91–96.
85.
DarwicheTCollumSDBiW, et alAlterations in cardiovascular function in an experimental model of lung fibrosis and pulmonary hypertension. Exp Physiol2019; 104(4): 568–579.
86.
VenalisPKumánovicsGSchulze-KoopsH, et alCardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol2015; 67(2): 508–516.